• [Translated article] Prurigiform Angiomatosis: A New Term for Describing the Prominent Dermal Angiomatoid Proliferation Underlying Epidermal Changes in Prurigo Nodularis/Lichen Simplex Chronicus
• <em>Staphylococcus aureus</em> proteases trigger eosinophil-mediated skin inflammation
• "When you do not feel comfortable in your skin, you cannot get out of it" - A Qualitative Interview Study exploring Psychosocial Impact and Coping Strategies among Patients with Prurigo Nodularis
• A case of bullous pemphigoid following administration of anti-IL-31 receptor A antibody
• A Case of Prurigo Nodularis Associated With Crohn's Disease Responding to Upadacitinib
• A Case of Superficial Papular Neuroma: A Rare Neural Neoplasm
• A Continuous Intestinal Absorption Model to Predict Drug Enterohepatic Recirculation in Healthy Humans: Nalbuphine as a Model Substrate
• A critical evaluation of nemolizumab for prurigo nodularis
• A Fleshy Mystery: Prurigo Nodularis
• A randomized, double-blinded, vehicle-controlled clinical trial of topical cryosim-1, a synthetic TRPM8 agonist, in prurigo nodularis
• A systematic review of interleukin-31 inhibitors in the treatment of prurigo nodularis
• Abrocitinib Monotherapy for Refractory Prurigo Nodularis: Report of Two Successful Cases
• Angiomatosis prurigiforme: una nueva entidad propuesta para la proliferacion angiomatoide dermica prominente subyacente a los cambios epidermicos de prurigo nodularis/liquen simple cronico
• Association between prurigo nodularis and behavioural patterns of attention-deficit/hyperactivity disorder in children with atopic dermatitis: A cross-sectional study
• Baseline eosinophil level may be a predictive indicator for the effectiveness of dupilumab in patients with prurigo nodularis: A single-center, real-world prospective study
• Baseline eosinophil level may be a predictive indicator for the effectiveness of Dupilumab in patients with prurigo nodularis: A single-center, real-world prospective study in China
• Bidirectional association between alopecia areata and prurigo nodularis: a population-based cohort study using TriNetX
• Characterization of Paediatric Prurigo Nodularis: A Multicentre Retrospective, Observational Study
• Cholestatic Pruritus Mimicking a Cutaneous Drug Eruption
• Chronic Prurigo
• Clinical and Temporal Characteristics of Malignancy-Associated Prurigo Nodularis: A Systematic Review
• Clinical Characteristics and Treatment Outcomes of Prurigo Nodularis: A Retrospective Study
• Comorbidities of prurigo nodularis in Chinese patients: A multicenter retrospective study
• Comorbidities, healthcare resource utilization &amp; treatment pattern among patients with prurigo nodularis, compared to a benchmark in Germany: A real-world evidence claims data study
• Comparing the efficacy of updated treatment choices for prurigo nodularis: A network meta-analysis
• Comprehensive plasma cytokine and chemokine profiling in prurigo nodularis reveals endotypes in Type 2 inflammation
• Consensus document on the diagnostic algorithm for chronic nodular prurigo
• Consensus on the diagnostic algorithm for chronic nodular prurigo
• Deciphering the enigma of itch sensation: insights and impact from a readability study
• Depression, Anxiety and Suicidal Ideation in Prurigo Nodularis: A Systematic Review and Meta-analysis
• Dermoscopy to differentiate clinically similar inflammatory and neoplastic skin lesions
• Development and Validation of a Patient-Reported Outcome Measure to Assess Disease Control in Chronic Prurigo
• Disease burden and treatment satisfaction in patients with prurigo nodularis in Japan
• Dupilumab bei einem 5-jährigen Kind mit Prurigo nodularis
• Dupilumab effectiveness in a case of prurigo nodularis and severe recalcitrant hidradenitis suppurativa
• Dupilumab for the Treatment of Prurigo Nodularis
• Dupilumab for Treatment of Prurigo Nodularis: Real-Life Effectiveness for up to 84 Weeks
• Dupilumab improves pruritus and skin lesions in patients with prurigo nodularis: Pooled results from 2 phase 3 trials (LIBERTY-PN PRIME and PRIME2)
• Dupilumab Therapy Modulates Circulating Inflammatory Mediators in Patients with Prurigo Nodularis
• Dupilumab: Mechanism of action, clinical, and translational science
• Dysregulation of the Skin-Liver Axis in Prurigo Nodularis: An Integrated Genomic, Transcriptomic, and Population-Based Analysis
• Effective response to upadacitinib in patients affected by prurigo nodularis and by atopic dermatitis with a predominant prurigo nodularis pattern: A multicenter case series study
• Efficacy and Safety of Abrocitinib in Prurigo Nodularis and Chronic Pruritus of Unknown Origin: A Nonrandomized Controlled Trial
• Efficacy and safety of nemolizumab and topical corticosteroids for prurigo nodularis: Results from a randomised, double-blind, placebo-controlled, phase II/III clinical study in patients aged 13 years
• Estimating meaningful change thresholds for Skin Pain-Numeric Rating Scale, Sleep-Numeric Rating Scale and Dermatology Life Quality Index in patients with prurigo nodularis
• Estimating the healthcare burden of Prurigo Nodularis in England: a CPRD database study
• Evaluating the Clinical Meaning of Dermatology Life Quality Index Scores Between Different Phenotypes of Atopic Dermatitis in Patients Before and After Biologic Therapy With Dupilumab
• Evaluation of the histopathological spectrum of skin biopsies in patients with chronic kidney disease: A single-center experience
• Ex Vivo Confocal Laser Scanning Microscopy in Rare Skin Diseases
• Eye Movement Desensitization Protocol for Urge to Reduce Scratching Behaviour in Patients with Prurigo Nodularis: A Pilot Study
• HIV-related exclusion criteria in atopic dermatitis and prurigo nodularis clinical trials
• IL-4 and IL-13 are not involved in IL-31-induced itch-associated scratching behaviour in mice
• Incident Comorbidity, Resource Use, and All-Cause Mortality Associated with Prurigo Nodularis: A United Kingdom Retrospective Database Analysis
• Increased cardiovascular risks and mortality in prurigo nodularis: a global cohort study
• INDIVIDUAL ARTICLE: Management of Prurigo Nodularis
• INDIVIDUAL ARTICLE: New Horizons in Our Understanding of Prurigo Nodularis and Its Management
• INDIVIDUAL ARTICLE: Patient Journey and the Burden of Systemic Comorbidities and Sequalae in Prurigo Nodularis
• INDIVIDUAL ARTICLE: Prurigo Nodularis: Current Clinicopathologic Overview and Psychodermatological Perspectives
• Kappa opioid agonists in the treatment of itch: just scratching the surface?
• Learning from nemolizumab: A promising therapy for prurigo nodularis
• Learnings from Nemolizumab: A Promising Therapy for Prurigo Nodularis
• Lebrikizumab Provides Rapid Clinical Responses Across All Eczema Area and Severity Index Body Regions and Clinical Signs in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis
• Long-term therapeutic response to dupilumab in patients affected by prurigo nodularis: A real-world retrospective study
• Mechanism underlying pruritus in recessive dystrophic epidermolysis bullosa: Role of interleukin-31 from mast cells and macrophages
• Molecular mechanisms of pruritus in prurigo nodularis
• Morgellons disease shows a lower quality of life than psoriasis, atopic dermatitis, and prurigo nodularis
• Nemolizumab - a new key player in the treatment of prurigo nodularis
• New insight into prurigo nodularis: Proadrenomedullin N-terminal 20 peptide mediates mouse mast cell activation via Mrgprb2
• New Laser Treatment for Prurigo Nodularis
• Non-Systemic Medication for the Treatment of Prurigo Nodularis: A Systematic Review
• Prevalence of malignancy and associated risk factors in prurigo nodularis patients: a retrospective study
• Prevalence of prurigo nodularis in Sweden
• Prevalence, Incidence and Treatment Patterns of Prurigo Nodularis in England: A Retrospective Database Analysis
• Prurigo nodularis following the lines of blaschko - A case of superimposed segmental manifestation
• Prurigo nodularis: A "Cinderella" disease with significant burden and a bright future
• Prurigo Nodularis: Moving Forward
• Prurigo Nodularis: New insights into pathogenesis and novel therapeutics
• Prurigo Nodularis: Pathogenesis and the Horizon of Potential Therapeutics
• Prurigo nodularis: the difference between knowing the path and walking the path
• Racial and geographic disparities in global prurigo nodularis clinical trials
• Recalcitrant Reactive Perforating Collagenosis Successfully Treated with Dupilumab: A Case Report
• Responder analysis using clinically meaningful thresholds: Post hoc analyses from randomized dupilumab clinical trials in patients with prurigo nodularis
• Severe cutaneous reaction with initiation of dupilumab for atopic dermatitis and prurigo nodularis: An unusual adverse effect
• Severity, impact on quality of life and mental health burden of pruritus in prurigo nodularis: a cross-sectional study of a diverse patient cohort
• Single-cell RNA sequencing reveals dysregulated POSTN+WNT5A+ fibroblast subclusters in prurigo nodularis
• Skin microdialysis detects distinct immunological patterns in chronic inflammatory skin diseases
• Spatial mass cytometry-based single cell imaging reveals a disrupted epithelial-immune axis in prurigo nodularis
• Successful response to upadacitinib in patients affected by prurigo nodularis and by atopic dermatitis with a predominant prurigo nodularis pattern: a multicenter case series study
• Successful treatment of prurigo nodularis with upadacitinib
• Successful treatment of refractory prurigo nodularis with abrocitinib
• Successful Treatment of Refractory Prurigo Nodularis with Alitretinoin and Methotrexate Combination Therapy
• Systemic Medication for the Treatment of Prurigo Nodularis-A Systematic Review
• Targeted Biologic Therapies in Chronic Prurigo: The Evolving Landscape of Chronic Prurigo Treatment
• The role of excimer light in dermatology: a review
• Treatment of chronic prurigo: update and perspectives
• Treatment of recalcitrant paediatric prurigo nodularis with tofacitinib, an exquisite example of bench-to-bedside translation of JAK-STAT expression
• Upadacitinib for moderate to severe atopic dermatitis with generalized prurigo nodularis
• Validation of a scoring algorithm for the clinician-reported outcome tool 'prurigo activity and severity (PAS)' based on clinical studies of dupilumab in adults with prurigo Nodularis
• When Multiple Conditions Converge: An Unusual Case of Infectious Aortitis in a Patient With Prurigo Nodularis and an Abdominal Aortic Aneurysm Endograft
• Worst Itch Numeric Rating Scale for Prurigo Nodularis: A Secondary Analysis of 2 Randomized Clinical Trials